# Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

> **NCT01610180** · PHASE2 · COMPLETED · sponsor: **Fondazione Progetto Ematologia** · enrollment: 18 (actual)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic
- Autoimmune Thrombocytopenic Purpura
- Autoimmune Thrombocytopenia
- Chronic Lymphocytic Leukemia
- Non Hodgkin's Lymphoma

## Interventions

- **DRUG:** Eltrombopag Olamine

## Key facts

- **NCT ID:** NCT01610180
- **Lead sponsor:** Fondazione Progetto Ematologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610180, "Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01610180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*